Tourmaline Bio, Inc. (TRML)
(Delayed Data from NSDQ)
$15.79 USD
+1.55 (10.88%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $15.77 -0.02 (-0.13%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
TRML 15.79 +1.55(10.88%)
Will TRML be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRML based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TRML
Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going
Here's What Could Help Tourmaline Bio, Inc. (TRML) Maintain Its Recent Price Strength
TRML: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing'
Other News for TRML
Analysts Offer Insights on Healthcare Companies: Tourmaline Bio (TRML), Amicus (FOLD) and Kura Oncology (KURA)
Tourmaline Bio price target lowered by $3 at Truist, here's why
Buy Rating Affirmed for Tourmaline Bio Amid Promising Clinical Trials and Strong Market Potential
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights